Navigation Links
Emphasys Medical Granted Expedited Review From FDA for Zephyr(R) Endobronchial Valve
Date:10/30/2007

each statistical significance. Investigators also reported on select patient subsets. In patients defined as having physiologically isolated target lung zones and correct Zephyr EBV placement, FEV1 was increased by 21% (p<0.0001).

While the PMA was granted expedited review, such grant does not change the standards associated with obtaining FDA approval, which the company will have to satisfy, and does not imply that the FDA has performed an in-depth evaluation of the safety and effectiveness of the Zephyr EBV.

About the Zephyr Endobronchial Valve

The Zephyr EBV is a small one-way silicone valve that is inserted into airways to prevent air from entering the diseased portion of the lung during inhalation, while allowing air and fluids to escape during exhalation. The Zephyr EBV is intended to mitigate the effects of emphysema by isolating the targeted diseased portion of the lung, causing a reduction in volume of the diseased region and allowing the healthier portions of the lung to function more normally. The Zephyr EBV has also been used for the treatment of lung air leaks in limited circumstances under a compassionate use protocol approved by the FDA on a case-by-case basis. Procedures using the Zephyr EBV are potentially reversible, if necessary, and the valves can be removed with standard bronchoscopic tools.

The Zephyr EBV is CE marked and has been sold on a limited basis in Europe and in certain Asia-Pacific regions including Australia, Hong Kong and Singapore. The Zephyr EBV system is limited to investigational use in the United States.

About Emphasys Medical

Based in Redwood City, California, Emphasys Medical is a medical technology company focused on developing and commercializing therapeutic devices for the treatment of patients with emphysema and other debilitating breathing disorders.

This press release contains statements that are forward-looking in nature. Statements preceded by the words believe, expect, antici
'/>"/>

SOURCE Emphasys Medical, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
2. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
5. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
6. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
7. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
8. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
9. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
10. Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting
11. World First Medical Treatment Announced by Researchers at Queen Mary University London and University of Leicester
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015 XRpro ... for drug discovery and development services which features ... the pharmaceutical industry, announced financial results for the ... Timothy C.  Tyson, Chairman of XRpro Sciences commented, ... successfully transition from development stage to commercial stage ...
(Date:3/27/2015)... 27, 2015  Valeant Pharmaceuticals International, Inc. (NYSE: ... its previously announced registered offering of common shares in ... Pursuant to the Offering, the Company issued 7,286,432 common ... aggregate gross proceeds of approximately $1.45 billion. On March ... and Exchange Commission a final prospectus supplement to its ...
(Date:3/27/2015)... , March 27, 2015 The International Myeloma ... myeloma patients while working toward prevention and a cure ... for introducing a federal resolution (H. Res. 174) that ... as "National Multiple Myeloma Awareness Month." Currently ... worldwide, and more than 110,000 new cases are diagnosed ...
Breaking Medicine Technology:XRpro Sciences Announces Fiscal 2014 Financial Results 2XRpro Sciences Announces Fiscal 2014 Financial Results 3XRpro Sciences Announces Fiscal 2014 Financial Results 4Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 3The International Myeloma Foundation (IMF) Secures the Introduction of a Federal Resolution Recognizing March 2015 as "National Multiple Myeloma Awareness Month" 2
(Date:3/29/2015)... York, NY (PRWEB) March 29, 2015 ... that conduct clinical trials and research, manage data ... to help their clients reach regulation standards. Contract ... pharmaceutical and medical device manufacturing sectors. Industry operators ... from early- to late-stage clinical research for Food ...
(Date:3/29/2015)... PORTLAND, Ore. (PRWEB) March 29, 2015 ... and Marion counties in Oregon to assess the feasibility ... youth with emotional and behavioral problems and their families. ... competition to select participants that will be provided technical ... The Oregon counties join six other national awardees chosen ...
(Date:3/29/2015)... IL (PRWEB) March 29, 2015 “Health ... Brickner, “and as we learn more about the cannabinoid ... In March Homeostasis: Publius’ Go Endo-Cannabinoid Update ... health, or endo-healing, is celebrated. Publius, of The Cannabis ... 2015 National Institutes of Health (PubMed) cannabinoid system (CS) ...
(Date:3/28/2015)... Tucson, AZ. (PRWEB) March 28, 2015 ... according to a new study by researchers ... (HSPH). , Produced with the support of the Coffee ... the journal Molecular Psychiatry this past fall, the study—one ... a meta-analysis of genomic data from more than 120,000 ...
(Date:3/28/2015)... With more than 4,500 scientists, clinicians and ... and musculoskeletal diseases gathered here for the World ... time in the 17-year history of the field’s ... is an emerging non-pharmaceutical protocol for enhancing bone ... Wolff’s law, osteogenic loading at multiples of body ...
Breaking Medicine News(10 mins):Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 4Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 2Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 3Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 4Health News:March Homeostasis: Publius’ Go Endo-Cannabinoid Update ~ New on the Bryan William Brickner Blog 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2
... submitted by Age Concern and London School of Hygiene and ... years are having an increased threat for disease due to ... that old age people are not spending the required amount ... eye care costs and are not undergoing the recommended 30 ...
... and doctors, and increases medical error risks, according to ... heating and cooling systems and by loud voices of ... short-term memory, according to the study by Johns Hopkins ... two-year research project, acoustics experts Ilene Busch-Vishniac and James ...
... that more lizard families than assumed till now are ... , The researchers, writing in the journal Nature ... like pain and swelling from lizard bites, which were ... of meat left between their teeth from their scavenging ...
... diabetes as a strong risk factor for sudden cardiac ... the disease.// ,The authors writing in the October ... prevalence of diabetes mellitus in industrialized countries is rapidly ... high risk for sudden cardiac death. ,The ...
... organisms, are exposed to ever-changing environments, oxidative stress, ... to defend themselves against all these insults, gain ... simply by ‘stealing’ genetic information from other better-adapted ... sex, known as horizontal gene transfer. ...
... A dengue fever vaccine full of promise is being tried ... of the GlaxoSmithKline vaccine //have been completed in the US ... be finished by the end of next year, Dr. Hans ... strong interest in making the vaccine available fast, given that ...
Cached Medicine News:Health News:More Lizards, Including Pets, Found Venomous 2Health News:Bacteria Evolve Armamentarium Against Antibiotics By ‘Stealing’ Gen 2
... Reichert MK1 Keratometer now utilizes ... consistent lighting, removing the need ... we didnt change are all ... made our Keratometer the worldwide ...
Agglutinating sera for serological identification of E. coli by slide and/or tube agglutination tests. Agglutinating sera are packaged 2 mL / vial....
... The innovative E.coli ... Pro-Lab offers definitive identification ... the use of a ... the possibility of cross-reactions ...
Inquire...
Medicine Products: